|
|||||
|
|
Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women |
|
| Authors: | Unadkat Jashvant D Wara Diane W Hughes Michael D Mathias Anita A Holland Diane T Paul Mary E Connor James Huang Sharon Nguyen Bach-Yen Watts D Heather Mofenson Lynne M Smith Elizabeth Deutsch Paul Kaiser Kathleen A Tuomala Ruth E |
| Affiliation: | Department of Pharmaceutics, University of Washington, Box 357610, Seattle, WA 98195, USA. jash@u.washington.edu |
| Abstract: | Human immunodeficiency virus-infected women (n=16) received indinavir (800 mg three times a day) plus zidovudine plus lamivudine from 14 to 28 weeks of gestation to 12 weeks postpartum. Two women and eight infants experienced grade 3 or 4 toxicities that were possibly treatment related. Indinavir area under the plasma concentration-time curve was 68% lower antepartum versus postpartum, suggesting increased intestinal and/or hepatic CYP3A activity during pregnancy. |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ | |